ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos491.9 M465.7 M502 M514.6 M602.9 M522.2 M2.14 BInvestigación y desarrollo271.1 M254.6 M276.2 M280.7 M267.7 M263.3 M1.09 BBeneficio operativo312.6 M394.8 M411.2 M307.1 M151.1 M477.6 M1.35 BTotal de ingresos no operativos77.5 M39.1 M-11 M41.3 M-60.7 M-18.6 M-49 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses44.2 M36.5 M-9.7 M38.6 M-63.9 M-90.1 M-125.1 MIngresos/gastos extraordinarios33.3 M2.6 M-1.3 M2.7 M3.2 M71.5 M76.1 MBeneficio antes de impuestos390.1 M433.9 M400.2 M348.4 M90.4 M459 M1.3 BParticipación en los beneficios———————Impuestos45.1 M70.3 M64.3 M56.1 M26.2 M78.3 M224.9 MParticipación minoritaria-1.3 M-1.6 M-1.7 M-800 K00-2.5 MOtros ingresos/gastos después de impuestos-15.7 M-3.6 M-4.7 M6 M-5.4 M-500 K-4.6 MBeneficio neto antes de actividades interrumpidas346.3 M365.2 M337.6 M293.1 M64.2 M380.7 M1.08 BOperaciones suspendidas39.3 M-7.2 M-4.4 M-2 M27 M020.6 MBeneficio neto385.6 M358 M333.2 M291.1 M91.2 M380.7 M1.1 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas385.6 M358 M333.2 M291.1 M91.2 M380.7 M1.1 BBeneficio básico por acción0.650.610.570.50.160.661.89Beneficio por acción diluido0.650.610.560.50.160.661.88Número medio de acciones ordinarias597.7 M586.9 M587 M584.7 M584.8 M579.2 M—Acciones diluidas599.3 M587.8 M587.9 M585.7 M585.8 M580.7 M—EBITDA285.6 M448.8 M465.4 M359.9 M-4.3 M537.8 M1.36 BEBIT203.4 M412.2 M427.3 M320.7 M-47 M496.9 M1.2 BCosto de los ingresos292.2 M301.6 M344.4 M345.2 M343 M362.6 M1.4 BOtros costes de producción———————Amortización y depreciación (flujo de caja)42.6 M36.6 M38.1 M39.2 M42.7 M40.9 M160.9 M
Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.